

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

THIS PAGE BLANK (USPTO)

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION
(PCT Rule 61.2)

To:

United States Patent and Trademark
Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 05 February 1998 (05.02.98)	To: United States Patent and Trademark Office (Box PCT) Crystal Plaza 2 Washington, DC 20231 ETATS-UNIS D'AMERIQUE in its capacity as elected Office
International application No. PCT/SE97/01164	Applicant's or agent's file reference 39234-45255
International filing date (day/month/year) 27 June 1997 (27.06.97)	Priority date (day/month/year) 05 July 1996 (05.07.96)
Applicant BRUNDELL, Jan et al	

1. The designated Office is hereby notified of its election made:

in the demand filed with the International Preliminary Examining Authority on:

13 January 1998 (13.01.98)

in a notice effecting later election filed with the International Bureau on:

2. The election was

BEST AVAILABLE COPY

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

THIS PAGE BLANK (USPTO)

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

H. Albihns Patentbyrå AB
Box 3137
S-103 62 Stockholm
Sweden

PCT

WRITTEN OPINION

(PCT Rule 66)

		Date of mailing (day/month/year)	29 -05- 1998
Applicant's or agent's file reference 39234-45255		REPLY DUE	within 45 days from the above date of mailing
International application No. PCT/SE97/01164	International filing date (day/month/year) 27.06.1997	Priority date (day/month/year) 05.07.1996	
International Patent Classification (IPC) or both national classification and IPC6 C 07 K 14/435, C 07 K 16/18, G 01 N 33/553			
Applicant AB Sangtec Medical et al			

1. This written opinion is the first (first, etc.) drawn by this International Preliminary Examining Authority.

2. This opinion contains indications relating to the following items:

- I Basis of the report
- II Priority
- III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV Lack of unity of invention
- V Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI Certain documents cited
- VII Certain defects in the international application
- VIII Certain observations on the international application

3. The applicant is hereby **invited to reply** to this opinion.

When? See the time limit indicated above. The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d).

How? By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3.
For the form and the language of the amendments, see Rules 66.8 and 66.9.

Also For an additional opportunity to submit amendments, see Rule 66.4.
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4bis.
For an informal communication with the examiner, see Rule 66.6.

If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.

4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: 05.11.1998

Name and mailing address of the IPEA/SE Patent- och registreringsverket Box 5055 S-102 42 STOCKHOLM Facsimile No. 08-667 72 88	Telex 17978 PATOREG-S	Authorized officer Patrick Andersson Telephone No. 08-782 25 00
--	-----------------------------	--

THIS PAGE BLANK (usp..)

WRITTEN OPINION

International application No.

PCT/SE97/01164

I. Basis of the report

1. This opinion has been drawn on the basis of *(Substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed".)*:

the international application as originally filed.

the description, pages _____, as originally filed,
pages _____, filed with the demand,
pages _____, filed with the letter of _____

the claims, Nos. _____, as originally filed,
Nos. _____, as amended under Article 19,
Nos. _____, filed with the demand,
Nos. _____, filed with the letter of _____

the drawings, sheets/fig _____, as originally filed,
sheets/fig _____, filed with the demand
sheets/fig _____, filed with the letter of _____

2. The amendments have resulted in the cancellation of:

the description, pages _____

the claims, Nos. _____

the drawings, sheets/fig _____

3. This opinion has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the supplemental Box (Rule 70.2(c)).

4. Additional observations, if necessary:

THIS PAGE BLANK (USPTO)

WRITTEN OPINION

International application No.

PCT/SE97/01164

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	<u>1-18</u>	YES
	Claims	_____	NO
Inventive step (IS)	Claims	_____	YES
	Claims	<u>1-18</u>	NO
Industrial applicability (IA)	Claims	<u>1-18</u>	YES
	Claims	_____	NO

2. Citations and explanations

The claimed invention relates to: a peptide consisting of at least one subfragment derived from human S-100b polypeptide, a monoclonal antibody binding the polypeptide, the use of the antibody or the polypeptide in an assay, and a kit using the antibody or the polypeptide.

The peptide according to the invention comprises a subfragment of human S-100b polypeptide showing at least 90% homology with SEQ. ID. NO. 2 or SEQ. ID. NO. 3.

The following documents are considered relevant:

A. Donaldson et al "Human S 100b protein: Formation of a tetramer from synthetic calcium binding site peptides", 1995, Protein Science, vol 4, pages 765-772

B. van Eldik LJ et al., "Production and characterization of monoclonal antibodies with specificity for the S-100B polypeptide of brain S-100B fractions", 1982, Proc Natl Acad Sci vol 81, pages 6034-6038

C. JP6109734

Document A discloses a polypeptide consisting of amino acid 1-46 of human S-100b polypeptide which contains SEQ. ID. NO. 2. It is most likely that this polypeptide will retain the same immunological properties as SEQ ID NO. 2. Thus the invention according to claims 1-2 is considered to be novel but not to involve an inventive step.

Document B discloses the production and characterisation of monoclonal antibodies with specificity for human S-100b, see page 6035, column 2 line 59-63; the antibodies are used in an assay for human S-100b.

. / .

THIS PAGE BLANK (USPTO)

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: V

The epitopes of the monoclonal antibodies are not disclosed, however, it is likely that these antibodies are reactive against the epitopes of claims 1-6 as S-100b is a small polypeptide. That being said, even though the antibodies according to claims 7-9 may be novel, they have not been shown to involve an inventive step.

Document A discloses the complete amino acid sequence for human S-100b. Epitope mapping a is well established method in the art, therefore the peptide according to claims 3-6 is considered to be novel, but not to involve an inventive step.

Document C discloses a method and a kit for determination of S-100 protein using antibodies immobilised on magnetic particles.

In view of these documents the uses and method of claims 10-18 are obvious for a person skilled. Thus, the invention according to claims 10-18 is considered to be novel but not to involve an inventive step.

THIS PAGE BLANK (USPTO)

PATENT COOPERATION TREATY

PCT

REC'D	19 OCT 1998
WIPO	PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 39234-45255	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/SE97/01164	International filing date (day/month/year) 27.06.1997	Priority date (day/month/year) 05.07.1996
International Patent Classification (IPC) or national classification and IPC6 C 07 K 14/435, C 07 K 16/18, G 01 N 33/553		
Applicant AB Sangtec Medical et al		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 4 sheets, including this cover sheet.

This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of _____ sheets.

3. This report contains indications relating to the following items:

- I Basis of the report
- II Priority
- III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV Lack of unity of invention
- V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI Certain documents cited
- VII Certain defects in the international application
- VIII Certain observations on the international application

Date of submission of the demand 13.01.1998	Date of completion of this report 28.09.1998
Name and mailing address of the IPEA/SE Patent- och registreringsverket Box 5055 S-102 42 STOCKHOLM Facsimile No. 08-667 72 88	Authorized officer Patrick Andersson Telephone No. 08-782 25 00

THIS PAGE BLANK (USPTO)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/SE97/01164

L Basis of the report

1. This report has been drawn on the basis of (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

the international application as originally filed.

the description, pages _____, as originally filed,
pages _____, filed with the demand,
pages _____, filed with the letter of _____,
pages _____, filed with the letter of _____

the claims, Nos. _____, as originally filed,
Nos. _____, as amended under Article 19,
Nos. _____, filed with the demand,
Nos. _____, filed with the letter of _____,
Nos. _____, filed with the letter of _____

the drawings, sheets/fig _____, as originally filed,
sheets/fig _____, filed with the demand
sheets/fig _____, filed with the letter of _____,
sheets/fig _____, filed with the letter of _____

2. The amendments have resulted in the cancellation of:

the description, pages _____

the claims, Nos. _____

the drawings, sheets/fig _____

3. This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the supplemental Box (Rule 70.2(c)).

4. Additional observations, if necessary:

THIS PAGE BLANK (USPTO)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/SE97/01164

V. Resoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	<u>1-18</u>	YES
	Claims	_____	NO
Inventive step (IS)	Claims	_____	YES
	Claims	<u>1-18</u>	NO
Industrial applicability (IA)	Claims	<u>1-18</u>	YES
	Claims	_____	NO

2. Citations and explanations

The claimed invention relates to: a peptide consisting of at least one subfragment derived from human S-100b polypeptide, a monoclonal antibody binding the polypeptide, the use of the antibody or the polypeptide in an assay, and a kit using the antibody or the polypeptide.

The peptide according to the invention comprises a subfragment of human S-100b polypeptide showing at least 90% homology with SEQ. ID. NO. 2 or SEQ. ID. NO. 3.

The following documents are considered relevant:

A. Donaldson et al "Human S 100b protein: Formation of a tetramer from synthetic calcium binding site peptides", 1995, Protein Science, vol 4, pages 765-772

B. van Eldik LJ et al., "Production and charaterization of monoclonal antibodies with specificity for the S-100B polypeptide of brain S-100B fractions", 1982, Proc Natl Acad Sci vol 81, pages 6034-6038

C. JP6109734

Document A discloses a polypeptide consisting of amino acid 1-46 of human S-100b polypeptide which contains SEQ. ID. NO. 2. It is most likely that this polypeptide will retain the same immunological properties as SEQ ID NO. 2. Thus the invention according to claims 1-2 is considered to be novel, industrially applicable, but not to involve an inventive step.

Document B discloses the production and characterisation of monoclonal antibodies with specificity for human S-100b, see page 6035, column 2 line 59-63; the antibodies are used in an assay for human S-100b.

.../...

THIS PAGE BLANK (USPTO)

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: V

The epitopes of the monoclonal antibodies are not disclosed, however, it is likely that these antibodies are reactive against the epitopes of claims 1-6 as S-100b is a small polypeptide. That being said, even though the antibodies according to claims 7-9 may be novel, industrially applicable, they have not been shown to involve an inventive step..


Document A discloses the complete amino acid sequence for human S-100b. Epitope mapping is a well established method in the art, therefore the peptide according to claims 3-6 is considered to be novel, industrially applicable, but not to involve an inventive step.

Document C discloses a method and a kit for determination of S-100 protein using antibodies immobilised on magnetic particles.

In view of these documents the uses and method of claims 10-18 are obvious for a person skilled. Thus, the invention according to claims 10-18 is considered to be novel, industrially applicable, but not to involve an inventive step.

5

... PAGE BLAN

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) Unknown	INTERNATIONAL APPLICATION NO. PCT/SE97/01164	ATTORNEY'S DOCKET NUMBER 100096.401		
17. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS <small>PTO USE ONLY</small>		
Basic National Fee (37 CFR 1.492(a)(1)-(5)):				
Search Report has been prepared by the EPO or JPO \$ 840.00				
International preliminary examination fee paid to USPTO (37 CFR 1.482) \$ 670.00				
No international preliminary examination fee paid to USPTO (cu CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$ 760.00				
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$970.00				
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)..... \$ 96.00				
ENTER APPROPRIATE BASIC FEE AMOUNT =			\$1906.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).			\$130.00	
Claims	Number Filed	Number Extra	Rate	
Total Claims	18 - 20 =	0	x \$ 18.00	\$0.00
Independent Claims	2 - 3 =	0	x \$ 78.00	\$0.00
Multiple dependent claim(s) (if applicable)			+ \$260.00	\$260.00
TOTAL OF ABOVE CALCULATIONS =		\$390.00		
Reduction by ½ for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (NOTE: 37 CFR 1.9, 1.27, 1.28)		\$0.00		
SUBTOTAL =		\$2296.00		
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		\$0.00		
TOTAL NATIONAL FEE =		\$2296.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property)		\$0.00		
TOTAL FEES ENCLOSED =		\$2296.00		
		Amount to be refunded:	\$0.00	
		charged	\$0.00	
<p>a. <input checked="" type="checkbox"/> A check in the amount of <u>\$2296.00</u> cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. in the amount of <u>\$</u> to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No.19-1090. A duplicate copy of this sheet is enclosed.</p>				
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>				
<p>SEND ALL CORRESPONDENCE TO:</p> <p>MAKI, David J. SEED AND BERRY 6300 Columbia Center 701 5th Avenue Seattle, WA 98104-7092 United States of America (206) 622-4900</p>				
<p> SIGNATURE</p> <p>David J. Maki NAME</p> <p>31,392 REGISTRATION NUMBER</p>				

THIS PAGE BLANK (OSF)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 97/01164

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07K 14/435, C07K 16/18, G01N 33/553

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07K, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE, DK, FI, NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, PAJ, CA, MEDLINE, BIOSIS, DBA, PCI GENBANK/EMBL/SWISSPROT/DDBJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	The Journal of Biological Chemistry, Volume 263, No 16, June 1988, Linda J. Van Eldik et al, "Synthesis and Expression of a Gene Coding for the Calcium-modulated Protein S100Beta and Designed for Cassette-based, Site-directed Mutagenesis" page 7830 - page 7837 --	1-6
A	Proc. Natl. Acad. Sci., Volume 81, October 1984, Linda J. Van Eldik et al, "Production and characterization of monoclonal antibodies with specificity for the S100Beta polypeptide of brain S100 fractions" page 6034 - page 6038	1-6
X	--	7-12, 16-18

 Further documents are listed in the continuation of Box C. See patent family annex.

- * Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "R" earlier document but published on or after the international filing date
- "I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed
- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

30.10.1997

29 October 1997

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Patrick Andersson
Telephone No. +46 8 782 25 00

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 97/01164

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>Protein Science, Volume 4, 1995, Craig Donaldson et al, "Human S100b protein: Formation of a tetramer from synthetic calcium-binding site peptides" page 765 - page 772</p> <p>--</p>	1-3
X	<p>Dialog Information Services, File 351, (World Patent Index), Dialog accession no. 009890614, WPI accession no. 94-170530/21, SRL KK: "Highly sensitive antigen determin.- comprises solidifying antibody on analyte antigen, blocking solid phase, reacting with sample, reacting with peroxidase", JP,A,6109734, 940422, 9421 (Basic)</p> <p>--</p> <p>-----</p>	13-15

THIS PAGE BLANK (USPTO)

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07K 14/435, 16/18, G01N 33/553		A1	(11) International Publication Number: WO 98/01471 (43) International Publication Date: 15 January 1998 (15.01.98)
(21) International Application Number: PCT/SE97/01164 (22) International Filing Date: 27 June 1997 (27.06.97)		(81) Designated States: AU, BR, CA, FI, HU, IL, JP, NO, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 9602677-8 5 July 1996 (05.07.96) SE		Published <i>With international search report.</i>	
(71) Applicant (for all designated States except US): AB SANGTEC MEDICAL [SE/SE]; P.O. Box 20045, S-161 02 Bromma (SE).			
(72) Inventors; and (75) Inventors/Applicants (for US only): BRUNDELL, Jan [SE/SE]; Sveavägen 78, S-113 59 Stockholm (SE). NYBERG, Lena [SE/SE]; Tallbacksvägen 30 B, S-756 45 Uppsala (SE).			
(74) Agents: BERG, S., A. et al.; H. Albihns Patentbyrå AB, P.O. Box 3137, S-103 62 Stockholm (SE).			

(54) Title: METHODS FOR DETERMINING THE PRESENCE OF BRAIN PROTEIN S-100

(57) Abstract

An assay method for determining the presence of the brain protein S-100 in a clinical sample which uses antibodies directed to epitopes in the region from ser1 to asn38 and from thr82 to glu93 of the amino acid sequence of the β subunit of human S100B is provided.

THIS PAGE BLANK (USPTO)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

THIS PAGE BLANK (USPS)

1
METHODS FOR DETERMINING THE PRESENCE OF BRAIN PROTEIN S-100

The present invention relates methods for diagnosis and follow-up of patients with cerebral dysfunction as well as melanoma cancer, by determining the presence of the 5 brain protein S-100. The invention also relates to peptides comprising useful antigenic determinants from S-100 as well as monoclonal antibodies binding to these peptides.

As is known, the nervous system contains a number of proteins unique to its various 10 cellular elements. The cellular disruption of nervous tissue and cells of neural origin, by any pathogenic process, trauma or by neurological diseases, results in the release of normal soluble endogenous cytoplasmic proteins into the cerebral extracellular fluid and ultimately to other body fluids including the cerebrospinal fluid (CSF) and blood (serum and plasma). Examples of representative soluble small molecule 15 weight proteins of this type can be found in the S100 protein family. A review of this family can be found in Zimmer et al., Brain Research Bulletin, Vol. 37, pp 417-429, 1995.

Following disruption of cell membranes, these proteins are released into the 20 extracellular fluid in accordance with a time course and in quantities relative to the pathogenesis of the disease process or the extent of the brain tissue damages. The proteins diffuse into the CSF and then the blood or directly into the blood. The above mentioned cell membrane disruption is reflected by the blood plasma or serum 25 levels of one or more of these antigens and markers. These protein antigens have the advantage of being stable and specific, not only for the brain, but for the cellular components in the brain. By following the relative release of the various nervous system protein antigens, it is possible to deduce the kind of destructive process occurring in the course of neurological diseases and/or the extent of possible brain 30 tissue damages. Information of this type permits the diagnosis, evaluation of severity and rate of progression of the above mentioned diseases and damages.

It is previously known to determine the amount of S-100 polypeptides in a clinical sample. US-A-4 654 313 discloses a radioimmunological assay method for S-100

protein. The patent document does neither mention anything about different kinds of S100-polypeptides nor about on which epitopes the assay method is based. The detection limit is declared to be 0.20 ng/ml but concentrations between 1.5 and 2.5 ng/ml is required in order to have less than 10% false positives. This concentration is 5 rather high. Moreover, in some countries it is not permitted to use radioactive methods in clinical assays.

It is also known to determine S-100 polypeptides by using ELISA-related methods. GB-A-2 109 931 discloses a solid-phase immunoanalysis method comprising the use 10 of enzyme-labelled antigens and particles coated with protein A on which antibodies are bound. S-100 proteins are only mentioned in claim 8 and nothing is revealed about the sensitivity of the method.

JP-A-6/109 734 describes a method suitable for analysing S-100 polypeptides, using 15 a first polyclonal antibody fixed to magnetic particles, and a second labelled polyclonal antibody. The method requires two different enzymes, namely horseradish peroxidase and alkaline phosphatase, and it comprises at least ten consecutive steps. The minimum detection limit is stated to be 0.02 ng/ml for cerebrospinal fluid and 0.06 ng/ml for bovine brain.

20

The complexity of clinical samples is often a serious problem. An assay method may give excellent results with artificial samples in the laboratory but quite a number of unreliable results might be obtained when the method is tested under clinical 25 conditions. When it comes to immunological assays the problems are often caused by an improper selection of antigenic determinants. One antibody in an assay comprising the use of two different antibodies, may be a hindrance to the other antibody when bound to the antigen to be determined. An improper selection of epitope for an antibody involved in the detection process may result in that the detection group is completely or partially embedded in a protein complex and not available 30 for detection. Different proteins present in the sample might interfere. Moreover, a method comprising many consecutive steps may give uncertain results for complex clinical samples, as the interference possibilities increase with the number of steps and added extra components.

There is always a need for improvement of methods for analysing substances of medical interest in clinical samples. An ideal clinical assay method should be quick, accurate and possible to perform with all types of clinical samples without 5 degeneration of the accuracy for certain types of specimen. It should also require a minimum of extra components. This applies to determination of S-100 polypeptides as well as other substances of medical interest.

Summary of the invention

10

Now it has turned out that by using antibodies directed to epitopes in the region from ser1 to asn38 and from thr82 to glu93 of the amino acid sequence of human S-100 β polypeptide, an improved clinical assay method for determining S-100 polypeptides and particularly the β subunit or isoform thereof is obtained. Hence, the main object 15 of the present invention is an assay method using monoclonal antibodies directed to these epitopes. Another object of the present invention relates to short peptides having sequences corresponding to parts of the amino acid sequence of the human S-100 β polypeptide from ser1 to asn38 and from thr82 to glu93. Yet another object of the present invention relates to analytical kits for carrying out the assay methods.

20

Detailed description of the invention

As already mentioned above it is often very difficult to outline methods for analysing clinical samples. It is necessary that the method has a high sensitivity and 25 gives accurate results. It is also very important that known and unknown constituents of the sample other than the analyte do not influence the results. The present invention relates to an immunological assay method for determining the presence and/or content of human S-100 polypeptide based upon a selection of suitable S-100 epitopes and corresponding antibodies which fulfil the above mentioned 30 requirements.

It has turned out that the selected epitope combinations provides tests and test kits where:

1. a high sensitivity is achieved;
- 5 2. the antibodies of the kit binds equally strong to the internal standard as to the analyte in the clinical sample;
3. the epitopes are chosen in such a way that the different antibodies do not interfere with each other when they bind to the analyte, i.e. that the epitopes are situated sufficiently distant from each other.

10

The epitopes of the present invention are all comprised in the human S-100 β polypeptide. Epitopes present within the amino acid sequences:

SELEKAMVALIDVFHQYSREGDKHKLKKSELKELINN (SEQ. ID. NO. 2)
and

15 TACHEFFEHE (SEQ.ID.NO. 3)

are preferred. Particularly preferred are epitopes comprised within the peptide AMVALIDVFHQYSREGDKHKLKKSELKELINN (SEQ. ID. NO. 4) and especially within the peptides REGDKHKLKKSELKEL (SEQ. ID. NO. 5) and EFFEHE (SEQ. ID. NO. 6).

20

The disclosed epitopes are, among all, used to construct peptides for inducing the formation of suitable antibodies on which the claimed assay method is based. These peptides mostly consist of up to 38 amino acids. The whole amino acid sequence of a peptide according to the present invention is derived from human S-100 β . These peptides may comprise variants wherein the original amino acid sequence is modified or altered by insertion, addition, substitution, inversion or deletion which preferably show at least 90% homology with the sequence of SEQ. ID. NO. 2 and SEQ.ID.NO.3 and retain essentially the same immunological properties. The peptides may also comprise multiples of certain epitopes, and in this case their sequence length may exceed 38 amino acids.

By the expression "sub-fragment" is meant a polypeptide sequence having a length of at least 6 amino acids.

5 The epitopes can also be used to construct fusion peptides comprising at least two distinct epitopes which, among all, can be used as internal standard in immunoassays.

Abbreviations

10 The following abbreviations are used:

S100	-S100 β
RT	-Room Temperature
BSA	-Bovine Serum Albumin
15 Mab(s)	-Monoclonal antibody(ies)
kD	-kiloDalton
ECL	-Enhanced Chemiluminescent Assay
CBB	-Commassie Brilliant Blue
LIA	-Luminometric Immuno Assay
20 IRMA	-Immuno Radio Metric Assay
ELISA	-Enzyme Linked ImmunoSorbent Assay
SDS-PAGE	-SodiumDodecylSulfate - PolyAcrylamideGelElectrophoresis
PBS	-Phosphate Buffered Saline
RLU	-Relative Light Units
25 NHS	-N-HydroxySuccinimide
EDC	-N-ethyl-N'-(dimethylaminopropyl)-carbodiimide
RAMFc	-RabbitAnti-MouseFc antibody
EDTA	-EtylenDiamineTetraAcetic acid
NaCl	-Sodium Chloride
30 NaN ₃	-Sodium azide
iv.	-intravenously
aa	-amino acid

ng	-nanogram
ml	-millilitre
mg	-milligram
HRP	-HorseRadish Peroxidase
5 h	-hour(s)
min	-minute(s)
sec	-second(s)

Experimental details common to all test procedures

10

The peptides were prepared by the methods disclosed in Merrifield (1963), J. Am. Chem. Soc., vol. 85, p 2149; Gutte et al.(1971), J. Biol Chem vol. 246, p. 1922; and Carpino et al. (1970), J Am Chem Soc vol. 92, p. 5748.

15

The monoclonal antibodies were prepared by the method according to Köhler et al.(1975), Nature vol. 256, p. 495; and Harlow et al.(1988), Antibodies. A Laboratory Manual. Cold Spring Harbor, p. 139.

Antigen and Standard preparations

20

Procedure for preparation and purification of S100 antigen prior to immunisation of Balb/c mice was according to Moore (Biochim. Biophys. Res. Comm. 1965, 19: 739 - 744) with a slight modification according to Haglid & Stavrou (J. Neurochem. 1973, 20:1523-1532). Briefly, bovine brain was homogenised in Tris buffer, pH 7.2.

25

The homogenate was centrifuged at 10.000 r.p.m. and the clear supernatant was used for further purification by ammonium sulphate precipitation. The fraction still soluble after saturation by ammonium sulphate was dialysed and purified by separation on a Sephadex G150 Sepharose (Pharmacia Biotech AB, Uppsala Sweden)chromatographic column followed by separation on a DEAE-sephadex

30

(ionic exchange) column (Pharmacia Biotech AB, Uppsala Sweden). The fraction eluted by 0.3 - 0.4 M NaCl was collected, desalted, lyophilised and used for further experiments.

Hybridoma construction.

Balb/c mice were immunised with purified S100 $\beta\beta$ intraperitonally in Freund's complete adjuvant and were given booster iv. injection 6 weeks later during 5 consecutive days. The spleen was removed on the fourth day after last injection and prepared for fusion. The myeloma cell line Sp2/0-Ag14 was used for fusion of Balb/c spleen cells.

Antibody purification and subclass determination.

10 Monoclonal antibodies were identified, extracted and purified from hybridoma supernatant according to Harlow & Lane Eds. in ANTIBODIES A LABORATORY MANUAL. Cold Spring Harbour Laboratory Press. New York 298-299 & 311. Briefly, positive hybridoma clones carrying supernatant with specific antibodies 15 were identified using ELISA with microtitreplate wells coated with S100 $\beta\beta$. Immunoglobulins were precipitated using saturated ammoniumsulphate and dialysed against 1.5 M Glycine, 3 M NaCl, pH 8.9. Dialysed material were affinity chromatography purified on an protein-A Sepharose (Pharmacia Biotech AB. Uppsala Sweden) column. Fractions were neutralised by addition of small volumes 20 of 1M Tris pH 8.0.

Epitope mapping

S100 β (monomer) epitopes for respective antibody was investigated by use of a 25 synthetic peptide library. Peptides were linked to nitro-cellulose filter membrane via an amide link, according to the manufacturer (Research Genetics, USA) and covers all ninety-one aa in the protein. In total the library consisted of thirty-one, all except one being ten aa-residues long synthetic peptides. Each peptide was consecutively shifted three aa towards the -COOH terminal end of the protein. Positive antibody- 30 binding was indicated by the use of a second anti-mouse antibody conjugated with IIRP and detected using an ECL assay (Amersham, UK).

Results:

Two binding sequences were found

Epitope 1

AMVALIDVFHQYSREGDKHKLKKSELKELINN (residues 6-38)(SEQ. ID.

5 NO.4)

and

Epitope 2

10 EFFEHE (residues No 86-91) (SEQ. ID. NO. 6)

Antibody reactivity

15 Purified antibodies reacting with the epitopes were checked for reactivity and affinity using the BIACore™ system (Pharmacia Biosensor AB, Uppsala Sweden). Briefly, in order to test the specificity of the antibodies, the RAMFc was immobilised onto the sensor chip CM5 NHS-ester activated surface, according to standard procedure, to provide approximately 600 RLU. Then each Mab was bound 20 to the RAMFc surface to approximately 300RLU, followed by the S100 $\alpha\alpha$ and the S100 standard (consisting of 50% S100 $\alpha\beta$ and 50% S100 $\beta\beta$) in separate experiments. All reactions were carried out in continuos flow of the phosphate buffer. The kinetics between antibodies and antigen was done similarly. S100 antigen was added to the chips at 200-450nM for reactivity measurements of the 25 antibody intended for the solid phase and at 1000-1500nM for measurements of the antibody intended for tracers. Kinetics was determined using the BIACore™ Kinetic evaluation 2.1. software (Pharmacia Biosensor AB, Uppsala Sweden). It can be concluded from the reactivity profile that the antibodies reactive with the epitopes are specific for the β -containing forms of S100 and not the α -containing form.

Example 1Development of an immunoluminometric procedure

5 Tracer antibody was conjugated with luminol. Briefly, ABEI (Sigma, St Louis, Ms) was linked with a diactivated ester (Etyleneglykolbis-succimidyl succinat, EGS). The ABEI-EGS-conjugate was next mixed with monoclonal antiS100-antibody in an approximately 50:5 molar ratio in 100 μ l of PBS pH 7.4, containing 15% acetonitrile and incubated 1 h at room temperature. The ABEI-conjugated antibody was purified
10 on a Sephacryl[®] S 300 HR (Pharmacia Biotech AB, Uppsala Sweden) gelfiltration column, and appropriate fractions were pooled and diluted in phosphate-buffer.

Preparation of antibody coated tubes for LIA.

15 Polystyrene tubes (Greiner, Germany) were incubated overnight at room temperature with 3 μ g of S100-antibodies in 300 μ l of PBS pH 7.5. The tubes were washed with 0.1% Tween20[®] in PBS. Next, tubes were blocked with a solution containing 0.9%BSA and 4% Saccarose and incubated for 24h. The solution was aspirated and the tubes allowed to dry.

20

LIA test procedure.

The test was conducted in a two step procedure by incubating 100 μ l of patient body fluid in antibody coated tubes, or S100 standard with 100 μ l of diluent (PBS +
25 5%BSA) and incubated at room temperature. After washing 200 μ l of the luminol-labelled antibody was added and a further 2 h of incubation was performed before measurement. After another washing the luminescence was developed using the LIA-mat starter service kit (Byk-Sangtec, Diezenbach Germany) and immediately measured as integrals over a period of 5 sec in luminometer (Berthold, Germany). In
30 order to convert the obtained light signal into concentration of S100 measurements on patient samples were compared with measurements on solutions with known

concentrations of S100 (standards). The detection limit (zero standard +3 standard deviations) was approximately 0.01 $\mu\text{g/l}$.

Preparation of a Standard curve

5

S100B protein was obtained from Medisera, Lund, Sweden, and diluted in PBS + 5% BSA. Dilutions contained: 0.10, 0.40, 2.00, 8.00 and 20.00 $\mu\text{g/l}$, of an S100 preparation consisting of 50 % of the $\beta\beta$ form and 50 % of the $\alpha\beta$ form. PBS + 5 % BSA was used as standard 0. Three measurements were carried out for each dilution.

10 The measured results as well as statistical calculations are presented in table 1 below:

Table 1

Concentration	Counts	Average	Calculated conc.	Average
15 Standard 0	1996		0 $\mu\text{g/l}$	
	2024		0 $\mu\text{g/l}$	
	2053		0.0019 $\mu\text{g/l}$	
		2024		0 $\mu\text{g/l}$
20 0.10 $\mu\text{g/l}$	3142		0.135 $\mu\text{g/l}$	
	2760		0.0647 $\mu\text{g/l}$	
	2988		0.105 $\mu\text{g/l}$	
		2963		0.10 $\mu\text{g/l}$
25 0.40 $\mu\text{g/l}$	5494		0.394 $\mu\text{g/l}$	
	5620		0.405 $\mu\text{g/l}$	
	5579		0.401 $\mu\text{g/l}$	
		5564		0.40 $\mu\text{g/l}$
30 2.00 $\mu\text{g/l}$	21430		2.049 $\mu\text{g/l}$	
	21028		1.988 $\mu\text{g/l}$	
	20869		1.966 $\mu\text{g/l}$	
		21109		2.00 $\mu\text{g/l}$

Concentration	Counts	Average	Calculated conc.	Average
8.00 µg/l	68389		7.823 µg/l	
	67013		7.677 µg/l	
5	74791		8.494 µg/l	
		70064		8.00 µg/l
20.00 µg/l	175560		22.12 µg/l	
	155141		18.54 µg/l	
	161052		19.51 µg/l	
10		163918		20.00
				µg/l

The lower detection limit was defined as three standard 0 determinations plus 3X the standard deviation value. For this measurement, it was calculated to be 0.006 µg/l.

15

Clinical determinations of S100 in serum

The S100 concentration was determined in serum from patients receiving heart bypass surgery and being connected to a heart-lung machine. The results are 20 presented in table 2 below:

Table 2

Patient	Counts	Average	Concentration	Average
1	94698		10.61 µg/l	
	98104		10.99 µg/l	
25		96401		10.80 µg/l
2	1716		Not detected	
	1478		Not detected	
	1597			Not detected
3	3762		0.23 µg/l	
30	3799		0.23 µg/l	
	3780			0.23 µg/l

Patient	Counts	Average	Concentration	Average
4	13158		1.04 $\mu\text{g/l}$	
	14183		1.15 $\mu\text{g/l}$	
		13670		1.10 $\mu\text{g/l}$
5	8788		0.66 $\mu\text{g/l}$	
	8580		0.64 $\mu\text{g/l}$	
		8684		0.65 $\mu\text{g/l}$
6	10301		0.78 $\mu\text{g/l}$	
	10100		0.77 $\mu\text{g/l}$	
10	10200			0.77 $\mu\text{g/l}$

Example 2

Development of an ELISA test procedure.

15

As tracer antibody was used monoclonal antiS100 antibody conjugated with β -galactosidase according to Harlow & Lane Eds. in ANTIBODIES A LABORATORY MANUAL, Cold Spring Harbour Laboratory Press, New York page 351.

Preparation of antibody coated microtiter wells for ELISA.

Microtiterplatewells (Corning, Denmark) were incubated overnight at +4°C with 2.5 μg of microtiter wells were finally washed three times with 0.05% Tween20[®] and air dried before use.

25

ELISA test procedure.

The ELISA was conducted in a multiple step incubation procedure.

100 μl of 1:1 diluted patient sample or 100 μl of S100 standard (0 - 20 $\mu\text{g/ml}$) was added to the wells.

The plate was incubated for 1.5h at RT under shaking.

The plates were washed three times with 300 μ l 0.05% Tween20[®] in PBS.

100 μ l of alkaline phosphatase conjugated tracer antibody was added and a further 1.5h of incubation on a shaker was performed.

The wells were then washed three times with 0.05% Tween20[®] in PBS.

5 100 μ l of a 5% o-nitro-phenyl- β -galactoside substrate solution was added and the plates were incubated with substrate for another forty-five minutes and colour is developed.

The colour development was stopped by the addition of 100 μ l 0.66M Na₂CO₃.

10 Each well of the plate was read at 405nm in a standard microtiterplate reader. In order to convert the obtained colour signal into concentration of S100, measurements on patient samples were compared with measurements on solutions with known concentrations of S100 (standards). The detection limit (zero standard +3 standard deviations) was approximately 0.2 μ g/l.

15 Result:

Standard (μ g/l)	0	0.5	1.5	5	15
λ 405	0.088	0.147	0.244	0.675	1.196

20

Example 3

Development of an immunoradiometric (IRMA) test procedure

25 IRMA tracer antibody conjugation

A monoclonal antiS100 antibody was conjugated with Iodine using the Chloramine T method according to Greenwood et al. (Biochem. J. 1963, 89:114-123). The specific activity was determined to be 520 \pm 80 MBq/mg

30

Preparation of antibody coated to polystyrene beads

Monoclonal anti S100 antibodies were coupled to polystyrene beads by the Glutaraldehyde coupling method according to Harlow & Lane Eds. in ANTIBODIES, 5 A LABORATORY MANUAL, Cold Spring Harbour Laboratory Press, New York, 533 & 536-537. Final blocking was by 1% BSA, 0.1% NaN₃ in PBS pH7.5.

IRMA test procedure.

10 100µl of patient sample or standard was added to polystyrene tubes together with 100µl PBS diluent. One polystyrene coated bead was added to each tube followed by incubation for 1 h at RT on a shaker. Next the beads were washed once with 2ml of demineralised water and 200µl of I-125 labelled tracer antibody was added and the tubes were incubated a further 2h on a shaker. After washing the radioactive signal on the bead was measured in a standard γ -counter. In order to convert the obtained radioactive signal into concentration of S100, measurements on patient samples were compared with measurements on solutions with known concentrations of S100 (standards). The detection limit (zero standard +3 standard deviations) was approximately 0.1 µg/l.

20

Example 4Use of IRMA test procedure for assay of S100 in serum from melanoma patients

25 The S100 based test procedure was applied on clinical questions relating to melanoma. Blood samples from patients with melanoma of various stages of cancer progression were collected in serum collecting tubes. Samples were then frozen and treated according to the test procedure described above in Example 3

30 Results:

Relationship to staging.

Clinical Stage I vs Clinical Stage II. In a study of 577 patients the geometric mean for Stage I was found to be 0.12 $\mu\text{g/l}$ and for Stage II the geometric mean was found to be 0.33 $\mu\text{g/l}$.
p-value < 0.001.

5

Example 5

Use of IRMA test procedure for assay of S100 in serum from melanoma patients

10 The S100 based test procedure was applied on clinical questions relating to melanoma. Blood samples from patients with melanoma of various stages of cancer progression were collected in serum collecting tubes. Samples were then frozen and treated according to the test procedure described above in Example 3.

15 Results:

Relationship to survival

Clinical Stage I vs Clinical Stage II and III. In a study with respect to survival performed on 643 patients the relative hazard and 95% confidence interval was 20 calculated. The relative hazard was found to be 12.3 and the confidence interval 5.6-27.2 with a p-value of <0.001

Example 6

25 Use of the S100 LIA-method for evaluation of the influence of extra corporal circulation equipment on the brain

The S100 based test procedure in Example 1 was applied on monitoring cerebral injury following extra corporeal circulation (ECC). Blood samples from patients 30 undergoing extra corporeal circulation were collected in serum tubes and treated according "Test procedure". Results

	Before start of ECC	End of ECC	1 day after sur- gery	2 days after sur- gery
S100 levels $\mu\text{g/l}$	0	1,67	0,21	0,13

In this group of patients the level of S100 in serum was elevated for at least 2 days after surgery.

Uncomplicated cases should return to normal levels within the first 24 hours (Ref P. 5 Johnson et al. J. Cardiothor .Vasc. Anaesthesia, 9:6 (1995) 694-99).

Example 7

10 Use of LIA test procedure for assay of S100 in serum from melanoma patients

The S100 based test procedure was applied on clinical questions relating to melanoma. Blood samples from patients with melanoma of various stages of cancer progression and blood donors were collected in serum collecting tubes. Samples 15 were frozen and treated according to the test procedure described above in Example 1.

Result: Of 136 patients with various stages of melanoma 25 had a level of S100 below 0.08 and of 100 blood donors tested on the same occasion 7 had a level equal 20 to or above 0.08 $\mu\text{g/l}$.

Example 8

25 The reliability of both the test and the S100 β polypeptide marker per se when diagnosing melanoma were investigated. On 252 patients with melanoma, serum was drawn before treatment was started and determination of the level of S100 β polypeptide was performed by the assay method disclosed in example 1. When a cut-off value of 0.16 $\mu\text{g/l}$ was used, the medium survival time of patients having a S100 β concentration above the cut-off value was 7 months, whereas the medium

survival time was more than 120 months for patients having a S100 β concentration below the cut-off value.

In a patient diagnosed with malignant melanoma, considered to show no evidence of
5 disease and monitored by the immunoradiometric assay method as disclosed in
example 3, elevated levels of S100 β were recorded 2 months prior to the appearance
of skin metastases and 6 months before metastases in organs were found.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: AB Sangtec Medical
- (B) STREET: P.O. Box 20045
- (C) CITY: Bromma
- (E) COUNTRY: Sweden
- (F) POSTAL CODE (ZIP): 161 02
- (G) TELEPHONE: +46 8 635 12 00
- (H) TELEFAX: +46 8 29 21 81

(ii) TITLE OF INVENTION: Methods for determining brain antigens

(iii) NUMBER OF SEQUENCES: 8

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 91 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Ser Glu Leu Glu Lys Ala Val Val Ala Leu Ile Asp Val Phe His Gln
1 5 10 15

Tyr Ser Gly Arg Glu Gly Asp Lys His Lys Leu Lys Lys Ser Glu Leu
20 25 30

Lys Glu Leu Ile Asn Asn Glu Leu Ser His Phe Leu Glu Glu Ile Lys
 35 40 45

Glu Gln Glu Val Val Asp Lys Val Asn Glu Thr Leu Asp Ser Asp Gly
 50 55 60

Asp Gly Glu Cys Asp Phe Gln Glu Phe Met Ala Phe Val Ala Met Ile
 65 70 75 80

Thr Thr Ala Cys His Glu Phe Phe Glu His Glu
 85 90

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Ser Glu Leu Glu Lys Ala Met Val Ala Leu Ile Asp Val Phe His Gln
 1 5 10 15

Tyr Ser Gly Arg Glu Gly Asp Lys His Lys Leu Lys Lys Ser Glu Leu
 20 25 30

Lys Glu Leu Ile Asn Asn
 35

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Homo sapiens*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Thr Ala Cys His Glu Phe Phe Glu His Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 33 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

- (vi) ORIGINAL SOURCE:

(A) ORGANISM: *Homo sapiens*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Ala Met Val Ala Leu Ile Asp Val Phe His Gln Tyr Ser Gly Arg Glu
1 5 10 15

Gly Asp Lys His Lys Leu Lys Lys Ser Glu Leu Lys Glu Leu Ile Asn
20 25 30

Asn

(2) INFORMATION FOR SEQ ID NO: 5:

- (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Arg Glu Gly Asp Lys His Lys Leu Lys Lys Ser Glu Leu Lys Glu Leu
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 6:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Glu Phe Phe Glu His Glu
1 5

(2) INFORMATION FOR SEQ ID NO: 7:

- (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Asp Lys His Lys Leu Lys Ser Glu Leu
1 5 10

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Lys Leu Lys Lys Ser Glu Leu Lys Glu Leu
1 5 10

Claims

1. A peptide consisting of at least one sub-fragment of the human S-100 β polypeptide comprising from 6 to 38 amino acids, where said sub-fragments show at least 90% homology with the sequence

SELEKAMVALIDVFHQYSREGDKHKLKKSELKELINN (SEQ. ID. NO. 2)

and/or the amino acid sequence

10

TACHEFFEHE (SEQ. ID. NO. 3)

and retain essentially the same immunological properties.

15 2. A peptide according to claim 1 **characterized** in that the sub-fragments are derived from the amino acid sequence:

SELEKAMVALIDVFHQYSREGDKHKLKKSELKELINN (SEQ. ID. NO. 2).

20 3. A peptide according to claim 2, which is

REGDKHKLKK (SEQ. ID. NO. 5);
DKHKLKKSEL (SEQ. ID. NO. 7); or
KLKKSELKEL (SEQ. ID. NO. 8).

25

4. A peptide according to claim 1, **characterized** in that the sub-fragments are derived from the amino acid sequence:

TACHEFFEHE (SEQ. ID. NO. 3).

30

5. A peptide according to claim 4, which is

EFFEHE (SEQ. ID. NO. 6).

6. A peptide according to claim 1, **characterized** in that it consists of at least one sub-fragment derived from the sequence according to SEQ. ID. NO. 2 and at least 5 one sub-fragment derived from the sequence according to SEQ. ID. NO. 3.
7. A monoclonal antibody or a fragment of such an antibody specifically binding a peptide according to anyone of the preceding claims.
- 10 8. A monoclonal antibody or an antibody fragment according to claim 7, specifically binding a peptide according to claim 2.
9. A monoclonal antibody or an antibody fragment according to claim 7, specifically binding a peptide according to claim 4.
- 15 10. Use of a monoclonal antibody or an antibody fragment according to anyone of claims 7-9 in immunological assay methods.
11. Use of a peptide according to anyone of claims 1-6 for eliciting antibodies.
- 20 12. Use of a peptide according to anyone of claims 1 - 6 in immunological assay methods.
13. A method of determining the presence of human S-100 β polypeptide in a sample 25 comprising the steps of:
 - letting the sample to be analyzed immunologically react with a first monoclonal antibody according to claim 8, said first antibody being coupled to a carrier;
 - 30 letting the sample immunologically react with a second monoclonal antibody according to claim 9, said second monoclonal antibody being provided with detection means;

Washing; and
detecting the amount of S-100 β polypeptide in the sample.

14. A method according to claim 13 where the detection means is a group having the
5 ability of emitting luminescence.
15. A method according to claim 14, where the carrier is a magnetic particle.
16. A kit for determining the presence of human S-100 β polypeptide in a sample,
10 comprising a peptide according to anyone of claims 1 - 6 and/or an antibody
according to anyone of claims 7 - 9.
17. A kit according to claim 16 comprising a first monoclonal antibody according to
claim 8 and a second monoclonal antibody according to claim 9, said first
15 monoclonal antibody being coupled to a carrier and said second monoclonal
antibody being provided with a detection means.
18. A kit according to claim 17, wherein said carrier is a magnetic particle and said
20 detection means is a group having the ability of emitting luminescence, such as
luminol.

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 97/01164

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07K 14/435, C07K 16/18, G01N 33/553
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07K, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, PAJ, CA, MEDLINE, BIOSIS, DBA, PCI GENBANK/EMBL/SWISSPROT/DDBJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	The Journal of Biological Chemistry, Volume 263, No 16, June 1988, Linda J. Van Eldik et al, "Synthesis and Expression of a Gene Coding for the Calcium-modulated Protein S100Beta and Designed for Cassette-based, Site-directed Mutagenesis" page 7830 - page 7837 --	1-6
A	Proc. Natl. Acad. Sci., Volume 81, October 1984, Linda J. Van Eldik et al, "Production and characterization of monoclonal antibodies with specificity for the S100Beta polypeptide of brain S100 fractions" page 6034 - page 6038 --	1-6 b
X		7-12, 16-18

Further documents are listed in the continuation of Box C.

See patent family annex.

- * Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "B" earlier document but published on or after the international filing date
- "I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

30.10.1997

29 October 1997

Name and mailing address of the ISA.
 Swedish Patent Office
 Box 5055, S-102 42 STOCKHOLM
 Facsimile No. + 46 8 666 02 86

Authorized officer

Patrick Andersson
 Telephone No. + 46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No. PCT/SE 97/01164
--

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	<p>Protein Science, Volume 4, 1995, Craig Donaldson et al, "Human S100b protein: Formation of a tetramer from synthetic calcium-binding site peptides" page 765 - page 772</p> <p>--</p>	1-3
X	<p>Dialog Information Services, File 351, (World Patent Index), Dialog accession no. 009890614, WPI accession no. 94-170530/21, SRL KK: "Highly sensitive antigen determin.- comprises solidifying antibody on analyte antigen, blocking solid phase, reacting with sample, reacting with peroxidase", JP,A,6109734, 940422, 9421 (Basic)</p> <p>-----</p>	13-15